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INTRODUCTION
Clinical studies and experimental animal models have
established that donor T cell recognition of alloantigen is the
primary event in the initiation of GVHD. Thereafter, there
occurs an amplification of immune reactivity which results in
dysregulated cytokine production and activation of secondary
immune effector cell populations [1–4]. Several lines of evi-
dence suggest that donor-derived ab T cells are the T cell
subset that plays the major role in the pathophysiology of
GVH reactivity. First of all, T cells initiate GVHD and ab T
cells constitute the vast majority of T cells, indirectly impli-
cating this subpopulation as most responsible for GVHD.
Second, immunohistologic studies in humans have shown
that infiltrating T cells in GVH lesions almost exclusively
express the ab, as opposed to the gd, T cell receptor (TCR)
when analyzed in skin, liver, or intestines of affected recipi-
ents [5–7]. A third line of evidence is that the residual ab T
cell content in the donor marrow graft (as opposed to the gd
T cell content) most closely correlates with the subsequent
development and severity of acute GVHD in recipients of T
cell–depleted HLA-identical sibling marrow grafts [8]. 
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ABSTRACT
The purpose of this study was to examine the ability of gd T cells to cause graft-vs.-host disease (GVHD) after allo-
geneic bone marrow transplantation (BMT) and to determine whether these cells offered any therapeutic advan-
tages relative to ab T cells. Due to the paucity of naive gd T cells in mice and humans, gd T cells (obtained from
ab T cell–deficient murine donors) were ex vivo activated and expanded in interleukin (IL)-2 so as to achieve suffi-
cient cell numbers and to serve as a more clinically feasible strategy. After transplantation into lethally irradiated
hosts, donor gd T cells were detected in target organs of GVHD such as the spleen and intestines 2 weeks after
BMT and constituted the primary T cell subpopulation. Large doses (1503106) of activated gd T cells, which we
have previously shown capable of facilitating engraftment in MHC-disparate recipients, failed to cause fatal GVHD
in lethally irradiated recipients of MHC-incompatible donor marrow grafts (C57BL/6 [H-2b]fi B10.BR [H-2k] and
C57BL/6 [H-2b]fi B6D2F1 [H-2b/d]). The absence of GVHD was confirmed by histologic analysis of target organs,
splenic B cell reconstitution, and appropriate negative selection in the thymus, that were all comparable to those
observed in mice transplanted with T cell–depleted BM only. While early splenic reconstitution was attributable to
donor gd T cells, analysis of durably engrafted chimeras 2 months posttransplant revealed that the vast majority of
donor splenic T cells expressed the ab T cell receptor. The results of secondary adoptive transfer assays showed
that these cells were tolerant of recipient alloantigens in vivo, demonstrating that gd T cells did not prevent the
subsequent development of donor anti-host tolerance in BM-derived ab T cells. When comparatively evaluated, the
minimal number of naive ab T cells necessary for donor engraftment caused significantly more fatal GVHD than
the corresponding minimal dose of activated gd T cells and thus had a superior therapeutic index. These studies
indicate that doses of activated gd T cells that are able to promote alloengraftment do not cause lethal GVHD in
mice transplanted with MHC-incompatible marrow grafts.
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The specific role of gd T cells, which represent a minor-
ity of T cells in both humans and rodents, in the pathophys-
iology of GVHD has been controversial. Whereas some
studies have presented indirect evidence that gd T cells con-
tribute to GVHD pathophysiology [9], others have not
found these cells capable of causing GVHD [10]. Under
certain experimental conditions, naive gd T cells derived
from transgenic mice have been shown to cause GVHD
[11]. The clinical relevance of gd T cells expressing only a
single TCR, however, is unknown. Moreover, the role in
GVHD of a polyclonal population of gd T cells, which is
more representative of the clinical situation, has not been
examined in a direct fashion. In our clinical transplant pro-
gram, we have observed high rates of engraftment in recipi-
ents of unrelated marrow grafts in which gd T cells are pref-
erentially spared from the depletion procedure, suggesting
that gd T cells may play a role in overcoming graft resis-
tance [12]. We have further found a direct correlation
between the gd T cell dose administered to patients and the
probability of engraftment [8]. This prompted us to examine
the role of gd T cells in facilitating engraftment in a major
histocompatibility complex (MHC)-incompatible murine
model using transgenic ab T cell–deficient animals as
donors so as to provide sufficient numbers of gd T cells. We
observed that large doses of naive gd T cells (203106) failed
to facilitate engraftment except in animals that also devel-
oped clinically significant GVHD [13]. Since further dose
escalation of naïve gd T cells was constrained by cell avail-
ability, we examined this question by ex vivo activating and
expanding gd T cells to achieve higher cell numbers. This
approach was also taken because of the low frequency of
these cells in the peripheral blood and bone marrow. There-
fore, the only way sufficient numbers of gd T cells are likely
to be obtainable for clinical application is through large-
scale expansion. These studies demonstrated that transplan-
tation with these escalated doses of activated gd T cells was
able to facilitate durable donor engraftment and promote
hematopoietic recovery [13]. Given that gd T cells are capa-
ble of promoting engraftment, the clinical application of
this strategy to allogeneic marrow transplantation is contin-
gent on the cells not being capable of causing significant
GVHD. We therefore sought to determine more critically
whether activated gd T cells caused significant GVHD,
assess what effect the cells had on splenic and thymic recon-
stitution, and determine if they possessed any therapeutic
advantage relative to ab T cells. 
MATERIALS AND METHODS
Mice
T cell receptor b–/b– (ab T cell–deficient, pure
C57BL/6 background, H-2b), normal C57BL/6 (H-2b),
AKR/J (H-2k), and B10.BR (H-2k) mice were purchased
from the Jackson Laboratory (Bar Harbor, ME). (C57BL/6
3 DBA/2) F1 mice (B6D2, [H-2b/d]) were purchased from
the National Institutes of Health (Bethesda, MD). All ani-
mals were housed in the American Association for Lab Ani-
mal Care (AALAC)-accredited Animal Resource Center of
the Medical College of Wisconsin. Mice received regular
mouse chow and acidified tap water ad libitum.
Flow cytometric analysis
Monoclonal antibodies (mAbs) conjugated to either flu-
oroscein isothiocyanate (FITC) or phycoerythrin (PE) were
used to assess chimerism in marrow transplant recipients.
FITC anti-Thy1.2 (clone 30-H12, rat IgG2b) was pur-
chased from Collaborative Biomedical Products (Bedford,
MA). FITC anti-Ly5 (B220, rat IgG2a) and PE anti-CD8
(clone CT-CD8a, rat IgG2a) were obtained from Caltag
(San Francisco, CA). PE anti-TCR ab (clone H57-597,
hamster IgG), PE anti-TCR gd (clone GL3, hamster IgG),
PE anti-CD3 (clone 145-2C11, hamster IgG), PE anti-Thy
1.1 (clone OX-7, mouse IgG1), PE anti-CD4 (clone GK
1.5, rat IgG2b), FITC anti-H-2Kb (clone AF6-885, mouse
IgG2a), Vb5-FITC (clone MR9-4, mouse IgG1), and Vb6-
FITC (clone RR4-7, rat IgG2b) were all purchased from
Pharmingen (San Diego, CA). Spleen, thymus, and intesti-
nal intraepithelial cells were obtained from chimeras at
defined intervals posttransplant and stained for two-color
analysis. Red cells were removed by lysis in distilled water.
Cells were analyzed on a FACS analyzer (Becton Dickinson,
Mountain View, CA) with Consort 32 computer support and
Lysis II software. Red cells and nonviable cells were exclud-
ed using forward and side scatter settings before analysis of
spleen and intestinal intraepithelial cell populations. Splenic
T cell chimerism was assessed within a lymphocyte gated
population, and thymic chimerism was evaluated using open
gates. The absolute number of donor T cells in the spleen
and intestinal epithelium was calculated by determining the
relative percentage of each population within the lympho-
cyte gate and multiplying by the total number of cells isolat-
ed. For quantification of splenic T cells, this calculation was
further adjusted through gating to account for the fact that
lymphocytes represented only a fractional number of total
spleen cells. Ten thousand cells were analyzed for each
determination whenever possible.
Ex vivo expansion of murine gd T cells
Spleen cells were obtained from TCR b–/b– donor ani-
mals and passed through nylon wool columns to remove
B cells. The resulting population typically comprised ~50%
cells expressing the gd TCR. Cells were then resuspended
in complete Dulbecco’s modified essential medium
(CDMEM) plus 5–10% fetal bovine serum (FBS) and cul-
tured in flasks precoated with an immobilized gd T cell–spe-
cific monoclonal antibody (GL4, hamster IgG, Pharmingen)
at a concentration of 5–10 µg/mL. Twenty-four hours after
the initiation of culture, human IL-2 (Cetus Corp., Nor-
walk, CT) was added at a concentration of 20–100 U/mL
(Cetus units). All cultures were split into fresh flasks as
needed to maintain a cell concentration of 0.5–1.53106
cells/mL. Cells were exposed to immobilized monoclonal
antibody for the first 3–4 days of culture and thereafter
grown only in medium plus IL-2 to allow for reexpression
of the gd TCR. After a total of 7–8 days in culture, cells
were counted, and the percentage of gd T cells was analyzed
by flow cytometry. Routinely, a total of 5–103108 cells was
obtained after expansion, with 95–99% of cells expressing
the gd TCR. Typically, 15–25% of activated gd T cells coex-
pressed CD8. CD4 expression was not detected on these
cells.
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Bone marrow transplantation
Bone marrow (BM) was flushed from donor femurs and
tibias with CDMEM and passed through sterile mesh filters
to obtain single-cell suspensions. BM was T cell–depleted in
vitro with anti-Thy1.2 monoclonal antibody plus low toxici-
ty rabbit complement (C6 Diagnostics, Mequon, WI). The
hybridoma for 30-H12 (anti-Thy1.2, rat IgG2b) antibody
was obtained from ATCC (Rockville, MD) and grown in
CDMEM plus 5% FBS. The culture supernatant was then
harvested, precipitated in ammonium sulfate, and dialyzed
against phosphate-buffered saline (PBS) before use in in
vitro depletion experiments. BM cells were then washed and
resuspended in DMEM before injection. To recover naive
T cells, spleen cell suspensions were obtained by pressing
spleens through wire mesh screens. Erythrocytes were
removed from cell suspensions by hypotonic lysis with ster-
ile distilled water. Naive T cells for admixture with T
cell–depleted (TCD) BM before transplantation were then
obtained by passing spleen cells once or twice through
nylon wool columns (Robbins Scientific, Sunnyvale, CA) to
remove B cells. The percentages of ab+ and gd+ T cells from
B6 donors were quantified by flow cytometry and defined as
Thy1.2+ ab TCR+ and Thy1.2+ gd TCR+, respectively. In
some experiments, naive T cells were defined as Thy1.2+
CD4+ and Thy 1.2+ CD8+. 
B10.BR, AKR/J, or B6D2F1 recipient mice were given
various doses of lethal total-body irradiation (900 cGy, 1100
cGy, or 1100 cGy, respectively) as a single exposure at a
dose rate of 75 cGy using a Mark I Cesium Irradiator (Shep-
herd, San Fernando, CA). Irradiated recipients then
received a single intravenous injection of TCD BM
(103106) with or without added naive or ex vivo activated
T cells. Recipients transplanted with activated gd T cells
received a dose of 1503106 cells. In some experiments, half
of the cells were given at the time of transplant and the
remaining cells were given 1 hour later to reduce the cell
density in the initial inoculum. In other experiments, the
total dose was given over 24 hours in four divided doses to
reduce immediate toxicity from the infusion of large num-
bers of activated cells. The total dose employed was based
on previous data which had shown that this number of gd
T cells was in the range required for consistent donor
engraftment in sublethally irradiated MHC-incompatible
recipients transplanted with TCD marrow grafts [13].
Isolation of intestinal intraepithelial lymphocytes
Intestinal intraepithelial lymphocytes (IELs) were
obtained according to the method of Whetsell et al. [14]
with minor modifications. Briefly, the small intestine was
removed from individual animals and the mesentery and
Peyer’s patches dissected from the tissue. Each intestine was
then cut into 0.5- to 1-cm segments, opened longitudinally
to expose the epithelium, and washed extensively in
CDMEM and 5% FBS until the supernatant was clear.
Intestinal pieces were placed into CDMEM and 5% FBS
plus 1 mM EDTA and incubated for 20 minutes (3 2) at
37°C. The supernatant was collected, centrifuged, and
resuspended in medium. Cells were passed through a prewet
nylon wool column to remove residual debris, washed, pel-
leted, and resuspended in a 44% isotonic Percoll solution.
Cells were centrifuged for 20 minutes at 1600 rpm. The cell
pellet was then resuspended in medium and cells were used
for FACS analysis to assess the extent of donor T cell
chimerism. 
Histological studies
Tissues were obtained from control and experimental
animals, fixed in 10% neutral buffered formalin, and
processed into paraffin blocks. Sections 4 µm thick were
prepared from each block and cut at two levels to optimize
sampling. Routine tissue hematoxylin and eosin sections
were prepared. For the evaluation of GVHD, tissue sections
were scored with the examiner blinded to the treatment
received by each animal. Tissues were scored positive for
GVHD if there was evidence of single-cell necrosis in the
skin, bile duct necrosis with or without infiltration in the
liver, crypt cell necrosis with or without infiltration in the
colon, or lymphocytic infiltration in the lung with associated
cell destruction. 
Statistical analysis
Group comparisons of donor T cell chimerism in the
spleen and thymus, splenic B cell content, and thymic size
were performed using the unpaired Student’s t test. A two-
tailed p value ≤0.05 was deemed to be significant. Survival
curves were constructed using the Kaplan-Meier product
limit and compared using the log rank rest. Mice that were
killed for secondary transfer experiments were censored
from the survival analysis at the time of death.
RESULTS
Activated gd T cells traffic to the spleen and intestines
early posttransplant
gd T cells constitute a minor T cell population in the
spleen of mice but represent the majority of T cells in the
intestinal epithelium. Since the spleen and the intestines are
both target organs in GVHD, we performed initial studies
to determine whether transplanted donor gd T cells were
detectable early posttransplant in lethally irradiated AKR
animals in either of these two sites, so as to exclude altered
trafficking as a mechanism by which GVHD might be abro-
gated. Animals were studied at two early time points (3 and
14 days post-BMT). Three days posttransplant, mice trans-
planted with activated gd T cells had a greater absolute
number of donor splenic T cells when compared with mice
receiving TCD BM only (2.53106 vs. 0.13106) (Table 1).
The difference in donor T cell chimerism between these
two groups was accounted for solely by the presence of
donor-derived gd T cells, since the number of donor ab T
cells was similar in both groups. The percentages of splenic
T cells that were donor as opposed to host in origin was 76
and 12%, respectively, in these two cohorts (data not
shown). Of note, virtually all of the gd T cells in the spleen
were of donor origin (94%) in mice transplanted with acti-
vated gd T cells. Donor-derived gd T cells were also
detectable in the intestinal epithelium and accounted for the
majority of donor T cells. The total number of donor T
cells was not substantially different between the two groups
at this early time point, however. When mice transplanted
with gd T cells were analyzed 2 weeks later (days 14–17),
the predominant donor T cell population again expressed
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the gd TCR in both the spleen and intestine. The absolute
number of donor gd+ T cells and CD3+ T cells were sub-
stantially higher in these animals when compared to control
mice, and gd+ T cells again accounted for the preponder-
ance of donor T cells. Moreover, 74 and 98% of all gd+
T cells found in the spleen and intestinal epithelium of these
mice, respectively, were donor-derived (data not shown).
The percentages of donor as opposed to host T cells in the
intestinal epithelium of group I vs. group II animals was 6
and 64%, respectively, while the percentages of donor T
cells in the spleen was 53 and 91%, respectively. These data
demonstrated that gd T cells were detectable and persisted
in the spleen and intestinal epithelium of recipients for at
least several weeks, and that these cells did not uniformly
undergo rapid cell death in vivo after transplantation.
Activated gd T cells do not cause lethal GVHD
To address whether activated gd T cells could cause
GVHD, we performed studies using two well-characterized
MHC-incompatible donor/recipient strain combinations. In
initial experiments, lethally irradiated B10.BR recipients
were transplanted with TCD B6 BM alone or together with
1503106 activated gd T cells. In this model, approximately
23106 naive T cells has been shown to be sufficient for the
induction of lethal GVHD in the majority of recipients [15].
Animals transplanted with 1503106 activated gd T cells had
survival equivalent to that observed in control mice (Fig. 1).
To further examine these mice for subclinical GVHD, we
performed detailed histologic analyses on tissues from the
mice that had survived for ~90 days. Examination of the
skin, lung, liver, and colon of these chimeras revealed no
significant differences between mice transplanted with or
without gd T cells. Specifically, three of 28 tissues were pos-
itive for GVHD in the former group while zero of 19 tissues
were positive in the latter cohort (p = 0.26 by Fisher’s exact
test). When splenic B cell reconstitution, which is also
known to be a sensitive indicator of GVHD in this model,
was comparatively analyzed, no significant differences were
observed, indicating that gd T cells did not cause a GVH-
associated reduction in B cell repopulation. Mice transplant-
ed with TCD BM alone (n=5) had a mean of 793106 splenic
B cells vs. 803106 for those transplanted with activated gd
T cells (n=7). Notably, animals in both groups had equiva-
lent levels of donor T cell chimerism (87 vs. 93%), so the
observed results could not be ascribed to differential donor
T cell engraftment.
To confirm that the lack of GVHD did not depend on
mouse strain, we examined this question using an alternative
model of GVHD in which donor and recipient are also
MHC-incompatible (B6fi B6D2). Lethally irradiated B6D2
recipients transplanted with 53106 naive B6 T cells
(GVHD control animals) all developed severe GVHD and
died within 25 days of BMT (Fig. 2). In contrast, there was
no observed mortality in B6D2 mice reconstituted with acti-
vated gd T cells, and these animals had survival comparable
to TCD BM control animals. Weight curves in these mice
were also similar to those observed in control mice (data not
shown). Thus, large doses of activated gd T cells failed to
cause lethal GVHD in these two different MHC-incompati-
ble donor/recipient strain combinations.
Table 1. Activated gd T cells traffic to the spleen and the intestinal epithelium early posttransplant
Number of donor cells (H-2Kb) expressing (310–6)
Day 3 Day 14-17
Spleen Intestine Spleen Intestine
Group CD3 ab gd CD3 ab gd CD3 ab gd CD3 ab gd
I 0.1 0.1 NE 0.2 0.1 0.1 0.5 0.2 0.2 0.05 0.01 0.01
II 2.5 0.2 2.4 0.3 0.1 0.3 12.5 1.7 12.6 1.9 0.2 1.8
Lethally irradiated (1100 cGy) AKR mice were transplanted with TCD B6 BM alone (group I) or together with 1503106 activated gd T cells from b–/b– (B6)
donors (group II). At defined time points, animals from each cohort were killed (n=3/group, day 3; n=2/group, day 14–17). Pooled spleen and intestinal intra-
epithelial lymphocyte cell suspensions were obtained and analyzed by flow cytometry to determine the absolute number of donor cells (H-2Kb+) that also coexpressed
CD3, ab TCR, or gd TCR. Data are presented as the mean number of cells from pooled cell suspensions. NE, not evaluable for technical reasons.
Figure 1. Activated gd T cells do not cause lethal GVHD in MHC-
incompatible recipients
Lethally irradiated (900 cGy) B10.BR recipients were transplanted with
TCD B6 BM alone ( h , n=5) or TCD B6 BM plus 1503106 activated gd
T cells ( j, n=7). Survival is depicted. Data are the cumulative results of two
similarly performed experiments.
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Long-term splenic donor T cell engraftment is accounted
for by ab and not gd T cells
We had observed that early posttransplant (within 2
weeks), gd T cells were the predominant donor T cell popu-
lation in the spleens of chimeras. Since gd T cells comprise
only a minority of the total splenic T cells in normal mice,
we questioned whether donor gd T cells persisted in the
spleens of these animals when examined at later time points
after marrow transplantation or whether animals ultimately
resembled normal mice with respect to the relative percent-
ages of each T cell subpopulation. When analyzed 60 days
after BMT, mice transplanted with TCD BM plus activated
gd T cells had donor T cell engraftment comparable to
mice reconstituted with TCD BM alone (data not shown).
In TCD BM control mice, nearly all donor T cells were ab
TCR+ (Table 2), similar to what was observed at early post-
transplant time points (Table 1). Conversely, while most
splenic donor T cells were primarily gd TCR+ in mice trans-
planted with activated T cells early after BMT, the majority
of donor T cells 60 days post-BMT expressed the ab TCR
(Table 2). gd T cells were present in higher numbers in
these animals than in TCD BM control mice (mean
0.13106 vs. 2.83106) but represented only ~10% of all
donor T cells. Thus, the relative percentage of gd T cells
detectable in the spleens of chimeras decreased with time
and ab T cells became the predominant donor T cell popu-
lation. The latter cells were necessarily bone
marrow–derived since the transplanted activated gd T cell
population was devoid of any ab T cells.
Splenic donor T cells in chimeric animals are tolerant of
recipient alloantigens
By performing secondary adoptive transfer assays, we
evaluated whether reconstituting splenic donor T cells,
which were primarily BM-derived ab TCR+ in animals
transplanted with activated gd T cells, were specifically tol-
erant of host alloantigens in vivo. Bone marrow and spleen
cells were obtained from B6 fi B6D2F1 chimeras 60 days
posttransplant, and equivalent numbers of each were trans-
planted into either lethally irradiated B6D2F1 or third-
party B10.BR recipients. The percentage of donor-derived
splenic T cells in these chimeras averaged 87%, demonstrat-
ing that chimeras were primarily engrafted with donor
T cells. B6D2 mice transplanted with chimeric (B6) T cells
failed to develop clinically significant GVHD, whereas the
majority of B10.BR recipients died of this complication
within 60 days of transplant (Fig. 3). Overall survival was
significantly greater in B6D2 recipients when compared
with B10.BR animals (p = 0.004). These data indicated that
donor-derived ab T cells that reconstituted in animals
transplanted with large doses of activated gd T cells were
tolerant of B6D2 host alloantigens but were capable of
mediating an alloresponse against third-party cells in vivo.
Transplantation with gd T cells therefore did not interfere
with the subsequent development of donor anti-host toler-
ance in BM-derived ab T cells.
Activated gd T cells do not cause GVHD in the thymus
The thymus is also known to be a target tissue for
GVHD, and animals undergoing GVHD have been shown
to have an increased number of single-positive CD4 and
CD8 cells with a corresponding reduction in double-positive
(CD4+CD8+) thymocytes [16,17]. Since tolerance appeared
to have been established as judged by secondary assays, we
performed additional experiments to directly examine for the
presence or absence of GVHD in the thymus of transplanted
recipients. Lethally irradiated B10.BR mice were transplant-
ed as above and analyzed 2 weeks posttransplant. As previ-
ously observed, mice reconstituted with activated gd T cells
had a greater percentage of donor T cells in the spleen
(mean 82 vs. 23%, p < 0.00005), with 94% of donor T cells
expressing the gd TCR. Analysis of thymic reconstitution
revealed that these animals had a significantly greater num-
ber of thymocytes (mean 713106 vs. 343106, p < 0.05), but
Figure 2. Activated gd T cells do not cause clinical GVHD in haplo-
type mismatched recipients
Lethally irradiated (1100 cGy) B6D2F1 recipients were transplanted with
TCD B6 BM alone ( s , n=10) or TCD B6 BM plus either 53106 naive B6
T cells ( h , n=10) or 1503106 activated gd T cells from b–/b– donors ( j ,
n=10). Survival is depicted. Data are the cumulative results of two similarly
performed experiments.
Table 2. ab T cells are the major splenic donor T cell population in durably
engrafted chimeras
Number of Donor gd Donor cells (310
–6) expressing
Group mice T cells added CD3 ab TCR gd TCR
I 3 None 10.2 8.9 0.1
II 4 1503106 23.1 21.4 2.8
Lethally irradiated (900 cGy) B10.BR recipients were transplanted with
103106 TCD B6 BM alone (group I) or together with 1503106 activated
gd T cells (group II). Animals were killed 60 days posttransplant, and spleen
cells were analyzed from individual chimeras by flow cytometry to determine
the absolute number of donor cells (H-2Kb+) that coexpressed CD3, ab TCR,
or gd TCR. Data are presented as the mean of individual data points.
Activated gd T Cells Do Not Cause Lethal GVHD
227B B & M T
equivalent percentages of double-positive CD4+CD8+ cells
(mean 75 vs. 77%, p = 0.66), when compared with control
mice. The percentage of single-positive CD4+ and CD8+ T
cells was also equivalent in both cohorts (data not shown).
These results demonstrated that transplantation with activat-
ed gd T cells did not effect any of the phenotypic changes
associated with GVHD in the thymus.
Negative selection in the thymus in animals transplanted
with activated gd T cells
A characteristic of GVHD in B6 fi B10.BR chimeras is
the failure to delete in the thymus T cells that are Vb5
+ or
Vb11
+. Consequently, these cells appear in the periphery of
recipients due to an absence of negative selection. We evalu-
ated whether negative selection occurred in the thymus of
animals transplanted with activated gd T cells by comparing
the splenic T cell phenotype of these mice with non-GVHD
and GVHD control animals. Mice transplanted with naive T
cells had a significantly higher absolute number of CD4+ and
CD8+ Vb5
+ T cells than mice transplanted with TCD BM
only (p < 0.02), consistent with the interpretation that these
mice had ongoing GVHD (Table 3). The absolute number
of Vb6
+ T cells was similar in both groups of mice, reflecting
the fact that these cells are not normally deleted in this strain
combination. Animals transplanted with activated gd T cells
had an absolute number of Vb5
+ CD4 and CD8 T cells not
significantly different from that observed in control animals
(p ‡ 0.38). These data indicated that negative selection of
Vb5
+ T cells occurred in these mice. The lack of Vb5
+ T cell
expansion was further evidence of an absence of GVH reac-
tivity in these chimeras. Since the majority of transplanted
activated gd T cells lacked expression of CD4 and CD8,
these data indicated that potentially host-reactive bone mar-
row–derived donor CD4+ and CD8+ T cells underwent
appropriate clonal deletion in the thymus.
Graft-facilitating doses of activated gd T cells 
cause significantly less GVHD than limiting numbers 
of naive ab T cells
We previously had shown that 53105 naive ab T cells is
the minimal number required to facilitate donor engraft-
ment in sublethally irradiated B6 fi AKR chimeras, while
80–1503106 activated gd T cells are necessary for durable
engraftment in the same model [13]. We therefore sought to
compare the relative ability of these two T cell doses to
induce GVHD so as to determine whether transplantation
with activated gd T cells offered any therapeutic advantage
over limiting numbers of ab T cells in this donor/recipient
strain combination. These studies were based on the
premise that limiting numbers of naive ab T cells would
presumably cause less GVHD than larger doses, and there-
fore this would be an alternative strategy by which to reduce
GVH-related toxicity. When lethally irradiated AKR mice
were transplanted with activated gd T cells, these animals
had similar survival and weight gain compared with animals
transplanted with TCD BM only (Fig. 4). B cell and thymic
recovery in these mice were comparable to that observed in
control animals (data not shown). Conversely, animals trans-
planted with limiting numbers of naive ab T cells had sub-
stantially more GVHD, as evidenced by reduced survival
and poorer weight gain posttransplant. These animals were
not evaluable for long-term immune reconstitution studies
because of early death. Collectively, these data indicated that
doses of activated gd T cells sufficient to facilitate allo-
engraftment did not cause clinically significant GVHD,
while minimal doses of naive ab T cells necessary for donor
engraftment resulted in substantial mortality from GVHD.
DISCUSSION
The clinical role of gd T cells in allogeneic BMT is
undefined. Moreover, the paucity of these cells in the
peripheral blood of humans has made potential clinical
administration problematic. For that reason, we have evalu-
ated the biological effects of ex vivo activated and expanded
gd T cells on engraftment and GVHD as a more clinically
feasible strategy. We have previously shown that large num-
bers of donor activated gd T cells (80–1603106) facilitates
engraftment of MHC-disparate TCD marrow grafts in sub-
lethally irradiated recipients [13]. Chimerism studies
revealed that 50–80% of splenic T cells and 70–95% of all
splenic cells were donor-derived. In contrast, animals trans-
planted with TCD marrow grafts averaged <10% donor
T cell chimerism. Analysis of the donor T cell phenotype in
the spleens of these chimeras demonstrated that the vast
majority expressed the ab T cell receptor, indicating that
transplantation of activated gd T cells enhanced the engraft-
ment of BM-derived donor T cells. Hematopoietic reconsti-
Figure 3. Donor-derived ab T cells which reconstitute in mice
transplanted with activated gd T cells are tolerant of recipient
alloantigens in vivo
Lethally irradiated (1100 cGy) B6D2F1 mice were transplanted with TCD
B6 BM plus 1503106 activated gd T cells. Sixty days after transplant, repre-
sentative chimeras (B6) were killed, and pooled suspensions of BM
(103106/mouse) and spleen cells (153106/mouse) were transplanted into
lethally irradiated B6D2 ( h , n=10) and B10.BR ( j , n=10) animals. Sur-
vival is depicted. Data are cumulative results from two similarly performed
experiments.
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tution was also augmented in these mice, as evidenced by
significantly higher white blood cell and platelet counts, fur-
ther proof for a graft-facilitating effect.
The aim of the current study was to determine whether
these cells were capable of causing GVHD across the MHC
barrier. The results herein demonstrated that transplanta-
tion with activated gd T cells did not result in clinically
significant GVHD when examined in several different
MHC-incompatible murine models. Both overall survival
and serial weight curves were comparable to those observed
in control (non-GVHD) mice. B cell reconstitution, which
is a sensitive indicator of GVHD, revealed that long-term
donor-engrafted chimeras had equivalent numbers of
splenic B cells when compared with control animals not
undergoing GVHD. The thymic phenotype in mice trans-
planted with activated gd T cells was also normal, indicating
a lack of clinically significant GVHD. Furthermore, host
reactive Vb5
+ T cells, which are increased in B6 fi B10.BR
chimeras undergoing GVHD, were present in the same
absolute numbers as in control mice, indicating that BM-
derived ab T cells underwent appropriate clonal selection in
the thymus. This conclusion was corroborated by secondary
adoptive transfer assays which demonstrated that these cells
were tolerant of recipient alloantigens but were capable of
immune reactivity against third-party cells. 
A central question was whether gd T cells were thera-
peutically beneficial relative to limiting numbers of naive ab
T cells. This issue spoke to whether similar results could be
obtained with respect to GVHD prevention by employing a
small number of naive ab T cells, a number minimally suffi-
cient for alloengraftment and therefore less likely to cause
GVHD. To that end, we performed a direct comparative
analysis between threshold numbers of naive ab and activat-
ed gd T cells to determine the ability of these respective cell
populations to induce GVHD. These studies clearly indicat-
ed that limiting numbers of naive ab T cells (0.53106)
induced significantly more GVHD than large doses of acti-
vated gd T cells (1503106). The data therefore provided
support for the premise that gd T cells may have a relative
therapeutic advantage in allogeneic marrow transplantation
by being capable of promoting engraftment without escalat-
ing toxicity from GVHD.
The mechanism by which animals transplanted with
activated gd T cells are protected from lethal GVHD in
these donor/recipient strain combinations is not resolved by
these studies. Several possible explanations deserve consid-
eration. One is that activation may have altered the migrato-
ry capabilities of these cells in such a way as to diminish
their capability to cause GVHD. Prior studies have shown
that activated T cells have altered migratory properties in
vivo when compared with unactivated T cells [18,19]. The
fact that these cells were detectable in the spleen and
intestines of chimeric mice >2 weeks posttransplant, howev-
er, was evidence that these cells were able to traffic to lym-
phoid tissue as well as target organs of GVHD. In the
spleen, specifically, one would expect that gd T cells would
have come into contact with antigen-presenting cells and
therefore would have had the ability to recognize host
alloantigens. 
Another possibility is that gd T cells are inherently less
capable of causing GVHD than ab T cells. Support for this
premise comes from prior studies showing that allorecogni-
tion by gd T cells differs from that observed for ab T cells
[20]. Specifically, recent data indicate that gd T cells may be
more immunoglobulin-like in their recognition properties,
and thus have a more flexible immune recognition reper-
Table 3. Animals transplanted with activated gd T cells undergo negative
selection in the thymus
Absolute number of splenic
CD4 (CD8) cells coexpressing:
Group Number of mice Vb5 (310
–6) Vb6 (310
–6)
TCD BM 3 0.04 (0.10)* 0.29 (0.16)†
Activated gd T cells 4 0.09 (0.07)* 0.16 (0.06)†
Naive T cells 4 0.35 (0.85) 0.17 (0.26)
Normal B10.BR 2 0 (0.06) 2.95 (1.55)
Normal C57BL/6 2 0.98 (2.3) 2.55 (1.23)
Lethally irradiated (900 cGy) B10.BR mice were transplanted with TCD B6
BM alone or together with either 1503106 activated gd T cells from b–/b–
donors or 23106 naïve T cells from normal B6 donors. Normal B10.BR and
C57BL/6 mice were included as controls. The absolute percentage of splenic
CD4 and CD8 T cells coexpressing either Vb5 or Vb6 was determined by
multiplying the total number of CD4+ or CD8+ T cells in the spleen cell sus-
pension as determined by flow cytometry by the percentage of each of these cell
types that coexpressed Vb5 or Vb6. 
*p ≤ 0.02 for both CD4+ and CD8+ cells compared with naive T cells.
†NS compared with naive T cells.
Figure 4. Activated gd T cells cause significantly less GVHD than
limiting numbers of ab T cells
Lethally irradiated (1100 cGy) AKR recipients were transplanted with TCD
B6 BM alone ( j , n= 8) or TCD B6 BM plus either 0.53106 naive ab T cells
( d , n=12) or 1503106 activated gd T cells ( h , n= 13). Survival is depicted.
Data are cumulative results from two similarly performed experiments.
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toire than ab T cells [20], which allows them to recognize
nonpolymorphic class I–like molecules or mycobacterial
nonapeptide antigens [21–26]. The frequency of alloreactive
gd T cell clones has also been shown to be much lower than
comparable ab T cell clones [27]. Therefore, the failure to
induce a GVH reaction may have been in part due to the
fact that the majority of these cells may not have been capa-
ble of mediating an effective alloreactive response necessary
to trigger a GVH reaction. Activated gd T cells have been
shown to be capable of facilitating alloengraftment [13],
however, suggesting that donor gd T cells are capable of
either eliminating or inactivating host immune cells which
can reject the marrow graft. One would presume that such
an interaction would also be an effective stimulus to induce
GVHD. 
A final possibility is that activation of gd T cells alters
the propensity of these cells to induce GVHD without com-
promising their ability to promote alloengraftment. We
have recently documented that activated CD4+ and CD8+
ab T cells have a reduced ability to mediate GVH reactivity,
although animals still exhibit clinical signs of GVHD [28].
This suggests that the activation process (anti-TCR mono-
clonal antibody plus IL-2) reduces the ability of the T cell to
mediate GVHD. Notably, with respect to activated CD8+
T cells, these cells retained their ability to facilitate engraft-
ment, although GVHD was not completely prevented. Prior
studies have shown that activation of both ab and gd T cells
makes these cells susceptible to apoptosis after religation of
a T cell receptor or after cytokine withdrawal [29–33].
These data raise the possibility that these cells are likely to
have a more limited life span in vivo, reducing their ability
to sustain a GVH reaction but not necessarily compromis-
ing their ability to facilitate engraftment. Supportive data
for this premise come from studies by Ferrarini et al. [34],
who demonstrated that cytotoxic activated gd T cells under-
went programmed cell death after killing of Daudi lym-
phoma target cells. The concurrent cell death of both
responder and target cells could explain the simultaneous
ability to facilitate engraftment without exacerbating
GVHD. Studies are currently underway to define if this is a
relevant mechanism by which GVHD is abrogated in these
animals.
Whether transplantation of activated gd T cells is of
clinical utility is unknown. The administration of gd T cells
to patients will likely require the capability for large scale ex
vivo expansion because of the need for sufficient cell num-
bers. To that end, we have recently performed studies which
demonstrate that the selective expansion of activated gd
T cells from human peripheral blood is feasible (W.R.D.,
C. Keever-Taylor, manuscript in preparation). After only 3
weeks in culture conditions designed to stimulate the prefer-
ential growth of these cells, a highly purified population of
gd T cells (~90%) free from detectable contaminating ab
T cells is obtainable. The total cell yield from a standard
buffy coat sample is >1.53108 gd T cells. Given that leuka-
pheresis cell yields are at least 10-fold greater, this approach
would yield the requisite 109–1010 activated gd T cells pre-
dicted from the animal studies to be necessary to facilitate
alloengraftment in humans.
The ability of gd T cells to promote engraftment with-
out causing GVHD is an observation that could be thera-
peutically advantageous if it can be corroborated in humans.
A specific advantage of this approach is that the therapeutic
index for activated gd T cells appears to be high in contrast
to naive ab T cells or even activated ab T cells, for which
GVHD is typically not abrogated even at low doses and
modest dose escalation can significantly increase the severity
of GVHD (Fig. 4) [28]. While the therapeutic index of acti-
vated ab T cells may be better than their resting counter-
parts [28], activated gd T cells appear to have an even supe-
rior index. This strategy would be particularly attractive in
nonmalignant disorders where disease recurrence is not a
concern and the amelioration of GVHD would not compro-
mise a graft-vs.-leukemia effect. Even in malignant diseases,
however, such an approach might be effective given murine
and human studies which have suggested that gd T cells
may play a role in tumor surveillance [35–37]. Clinical stud-
ies will ultimately be required to determine if these cells
possess any advantages relative to ab T cells in reducing
complications from allogeneic BMT. 
ACKNOWLEDGMENTS
We wish to thank Wendy Wozney for assistance with
preparation of the manuscript. We also thank Tina Agostini
and Sanja Vodanovic-Jankovic for technical assistance.
REFERENCES
1 Abhyankar S, Gilliland DG, Ferrara JLM: Interleukin-1 is a critical
effector molecule during cytokine dysregulation in graft versus host dis-
ease to minor histocompatibility antigens. Transplantation 56:1518,
1993.
2 Guillen FJ, Ferrara J, Hancock WW, Messadi D, Fonferko E, Burakoff
SJ, Murphy GF: Acute cutaneous graft-versus-host disease to minor his-
tocompatibility antigens in a murine model. Evidence that large granu-
lar lymphocytes are effector cells in the immune response. Lab Invest
55:35, 1986.
3 McCarthy PL Jr, Abhyankar S, Neben S, Newman G, Sieff C, Thomp-
son RC, Burakoff SJ, Ferrara JL: Inhibition of interleukin-1 by an inter-
leukin-1 receptor antagonist prevents graft-versus-host disease. Blood
78:1915, 1991.
4 Piguet PF, Grau GE, Allet B, Vassalli P: Tumour necrosis
factor/cachetin is an effector of skin and gut lesions of the acute phase
of graft-versus-host disease. J Exp Med 166:1280, 1987.
5 Diamond D, Chang K, Jenkins K, Forman S: Immunohistochemical
analysis of T cell phenotypes in patients with graft-verus-host disease
following allogeneic bone marrow transplantation. Transplantation
59:1436, 1995.
6 Norton J, Al-Saffar N, Sloane JP: Immunohistological study of dis-
tribution of gd lymphocytes after allogeneic bone marrow transplanta-
tion. J Clin Path 45:1027, 1992.
7 Roy J, Platt JL, Weisdorf DJ: The immunopathology of upper gas-
trointestinal acute graft-versus-host disease. I. Lymphoid cells and
endothelial adhesion molecules. Transplantation 55:572, 1993.
8 Kawanishi Y, Passweg J, Drobyski WR, Rowlings P, Cook-Craig A,
Casper J, Pietryga D, Garbrecht F, Camitta B, Horowitz M, Juckett M,
Margolis D, Flomenberg N, Keever-Taylor CA: Effect of T cell subset
dose on outcome of T cell-depleted bone marrow transplantation. Bone
Marrow Transplant 19:1069, 1997.
9 Ellison CA, MacDonald GC, Rector ES, Gartner JG: gd T cells in the
pathobiology of murine acute graft-versus-host disease. J Immunol
W.R. Drobyski, D. Majewski, and G. Hanson
230
155:4189, 1995.
10 Tsuji S, Char D, Bucy RP, Simonsen M, Chen CH, Cooper MD: gd T
cells are secondary participants in acute graft-versus-host reactions ini-
tiated by CD4+ ab T cells. Eur J Immunol 26:420, 1996.
11 Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Barrett TA, Bluestone
JA, Vallera DA: Lethal murine graft-versus-host disease induced by
donor gd expressing T cells with specificity for host nonclassical major
histocompatibility complex class Ib antigens. Blood 87:827, 1996.
12 Drobyski WR, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Law-
ton C, Keever C, Baxter-Lowe LA, Camitta B, Garbrecht F, Pietryga D,
Hansen R, Chitambar CR, Anderson T, Flomenberg N: Effect of T-cell
depletion as graft-versus-host disease prophylaxis on engraftment,
relapse, and disease-free survival in unrelated marrow transplantation
for chronic myelogenous leukemia. Blood 83:1980, 1994.
13 Drobyski WR, Majewski D: Donor gd T lymphocytes promote allo-
geneic engraftment across the major histocompatibility barrier in mice.
Blood 89:1100, 1997.
14 Whetsell M, Mosley L, Whetsell L, Schaefer F, Miller K, Klein J:
Rearrangement of junctional-site sequence analyses of T-cell receptor
gamma genes in intestinal intraepithelial lymphocytes from murine
athymic chimeras. Mol Cell Biol 11:5902, 1991.
15 Blazar BR, Carroll SF, Vallera DA: Prevention of murine graft-ver-
sus-host disease and bone marrow alloengraftment across the major his-
tocompatibility barrier after donor preincubation with anti-LFA1
immunotoxin. Blood 78:3093, 1991.
16 Desbarats J, Lapp WS: Thymic selection and thymic major histo-
compatibility complex class II expression are abnormal in mice under-
going graft-versus-host reactions. J Exp Med 178:805, 1993.
17 Fukushi N, Arase H, Wang B, Ogasawara K, Gotohda T, Good RA,
Onoe K: Thymus: a direct target tissue in graft-versus-host reaction
after allogeneic bone marrow transplantation that results in abrogation
of self-tolerance. Proc Natl Acad Sci U S A 87:6301, 1990.
18 Dailey MD, Fathman CG, Butcher EC, Pillemer E, Weissman I:
Abnormal migration of T lymphocyte clones. J Immunol 128:2134,
1982.
19 Dailey MD, Gallatin WM, Weissman IL: The in vivo behavior of T
cell clones: altered migration due to the loss of the lymphocyte surface
homing receptor. J Mol Cell Immunol 2:27, 1985.
20 Schild H, Mavaddat N, Litzenberger C, Ehrlich EW, Davis MM,
Bluestone JA, Matis L, Draper PK, Chien YH: The nature of major histo-
compatibility complex recognition by gd T cells. Cell 76:29, 1994.
21 Matis LA, Fry AM, Cron RQ, Cotterman MM, Dick RF, Bluestone JA:
Structure and specificity of a class II MHC alloreactive gd T cell recep-
tor heterodimer. Nature 245:746, 1989.
22 Matis LA, Cron R, Bluestone JA: Major histocompatibility complex-
linked specificity of gd receptor-bearing T lymphocytes. Nature
330:262, 1987.
23 Ito K, van Kaer L, Bonneville M, Hsu S, Murphy DB, Tonegawa S:
Recognition of the product of a novel MHC TL region gene (27b) by a
mouse gd T cell receptor. Cell 62:549, 1990.
24 Porcelli S, Brenner MB, Greenstein JL, Balk SP, Terhorst C, Bleicher
PA: Recognition of clusters of differentiation 1 antigens by human
CD4– CD8– cytolytic T lymphocytes. Nature 341:447, 1989.
25 Vidovic D, Roglic M, McKune K, Guerder S, MacKay C, Debic Z: Qa-
1 restricted recognition of foreign antigen by a gd T-cell hybridoma.
Nature 340:646, 1989. 
26 Morita CT, Beckman EM, Bukowski JF, Tanaka Y, Band H, Bloom
BR, Golan DE, Brenner MB: Direct presentation of nopeptide prenyl
pyrophosphate antigens to human gd T cells. Immunity 3:495, 1995.
27 Kabelitz D, Bender A, Schondelmaier S, daSilva Lobo ML, Janssen O:
Human cytotoxic lymphocytes. V. Frequency and specificity of gd+
cytotoxic lymphocyte precursors activated by allogeneic or autologous
stimulator cells. J Immunol 145:2827, 1990.
28 Drobyski WR, Majewski D, Ozker K, Hanson G: Ex vivo anti-CD3
antibody-activated donor T cells have a reduced ability to cause lethal
murine graft-versus-host disease but retain their ability to facilitate
alloengraftment. J Immunol 161:2610, 1998.
29 Wesselborg S, Janssen O, Kabelitz D: Induction of activation-driven
death (apoptosis) in activated but not resting peripheral blood T cells. J
Immunol 150:4338, 1993.
30 Janssen O, Wesselborg S, Heckl-Ostreicher B, Pechhold K, Bender A,
Schondelmaier S, Moldenhauer GS, Kabelitz D: T cell receptor/CD3 sig-
naling induces death by apoptosis in human T cell receptor gd+ T cells.
J Immunol 146:35, 1991.
31 Wesselborg S, Janseen D, Kabelitz D: Induction of activation-driven
death (apoptosis) in activated but not resting peripheral blood T cells. J
Immunol 150:4338, 1993.
32 Radvanyi LG, Mills GB, Miller RG: Religation of the T cell recep-
tor after primary activation of mature T cells inhibits proliferation and
induces apoptotic cell death. J Immunol 150:5704, 1993.
33 Akbar A, Borthwick N, Wichremasinghe R, Panayiotidis P, Pilling D,
Bofill M, Krajewski S, Reed JC, Salmon M: Interleukin 2 receptor com-
mon g-chain signaling cytokines regulated activated T cell apoptosis in
response to growth factor withdrawal. Eur J Immunol 26:294, 1996.
34 Ferrarini M, Heltai S, Toninelli E, Sabbadini M, Pelliciari C, Man-
fredi AA: Daudi lymphoma killing triggers the programmed cell death
of cytotoxic Vg9/Vd2 T lymphocytes. J Immunol 156:192, 1995.
35 Penninger JM, Wen T, Timms E, Potter J, Wallace VA, Matsuyama
T, Ferrick D, Sydora B, Kronenberg M, Mak TW: Spontaneous resistance
to acute T-cell leukaemias in TCRVg1.1Jg4Cg4 transgenic mice.
Nature 375:241, 1995.
36 Fisch P, Malkovsky M, Kovats S, Sturm E, Braakman E, Klein BS,
Voss SD, Morrissey LW, DeMars W, Welch WJ, Bolhuis RLH, Sondel PM:
Recognition by human Vg9+/Vd2+ T-cells of a GroEL homolog on
Daudi Burkitt’s lymphoma cells. Science 250:1269, 1990.
37 Bensussan A, Lagabrielle J, Degos L: TCR gd bearing lymphocyte
clones with lymphokine-activated killer activity against autologous
leukemic cells. Blood 73:2077, 1989.
